Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp306 | Osteoporosis: treatment | ECTS2014

The effect of bisphosphonate treatment on sclerostin levels in postmenopausal osteoporosis: the TRIO study

Gossiel Fatma , Naylor Kim , McCloskey Eugene , Peel Nicola , Walsh Jennifer , Paggiosi Margaret , Eastell Richard

Treatment of postmenopausal osteoporosis with bisphosphonates reduces bone resorption and formation. Sclerostin, an osteocyte regulator of bone formation may be involved in these changes. Some studies have reported an increase in sclerostin associated with bisphosphonate treatment while others have reported a decrease. The aims were to determine the effect of bisphosphonates on i) circulating sclerostin and ii) PINP in postmenopausal women with osteoporosis. We studied 92 post...

ba0003pp330 | Osteoporosis: treatment | ECTS2014

Determinants of bone turnover marker response to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study

Naylor Kim , Paggiosi Margaret , Gossiel Fatma , McCloskey Eugene , Peel Nicola , Walsh Jennifer , Eastell Richard

Three oral bisphosphonates ibandronate, alendronate, and risedronate are commonly used for the treatment of osteoporosis but they have not previously been compared in the same study. Our aim was to identify determinants of change in bone turnover markers (BTM) in response to these bisphosphonates in a 2-year randomised parallel group trial. We recruited 171 postmenopausal osteoporotic women (<85 years) who were randomised to receive ibandronate (150 mg monthly), alendronat...

ba0005oc3.4 | Clinical trials, FGF-23 and focal osteoporosis | ECTS2016

The response of fibroblast growth factor-23 to teriparatide in postmenopausal osteoporosis

Gossiel Fatma , McCloskey Eugene , Walsh Jennifer , Naylor Kim , Peel Nicola , Eastell Richard

FGF-23 is a phosphate regulating hormone and its production may be stimulated by circulating levels of 1,25-dihydroxyvitamin D (1,25-(OH)2D). Teriparatide administration increases levels of 1,25-(OH)2D, however it is unclear whether this mediates changes in FGF-23 levels. The aims were i) to determine the effect of teriparatide treatment on circulating levels of FGF-23 and 1,25-(OH)2D and ii) to describe the time course of effect in postmenopau...

ba0003oc6.3 | Osteoporosis treatment and the effects of physical activity | ECTS2014

Vitamin D is low in obesity, and this is due to greater volume of distribution

Walsh Jennifer S , Evans Amy L , Bowles Simon , Naylor Kim E , Gossiel Fatma , Jacques Richard , Schoenmakers Inez , Jones Kerry S , Eastell Richard

Low circulating levels of total 25-hydroxyvitamin D (25OHD) have been reported in obese people of different ethnicities in several countries. Low total 25OHD in obesity could be due to lower binding proteins (with normal free 25OHD), lower dietary intake or sunlight exposure, greater volume of distribution (pool size) or more rapid metabolic clearance.The aims of this study were to determine if free 25OHD and 1,25-dihydroxyvitamin D (1,25(OH)2...